title: PCSK9 and lipid lowering drugs.
abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a novel circulating protein, which plays an important role in the regulation of cholesterol metabolism. Over the past decade, experimental and clinical studies have established that over- or poor expression of PCSK9 had a key impact not only on circulating PCSK9 and low density lipoprotein cholesterol (LDL-C) levels but also on cardiovascular risk and atherosclerotic process. Since the first discovery of PCSK9-related gene in 2003, factors that can influence circulating PCSK9 concentration are of great interest in a variety of medical fields, especially in pharmacology. In this review we focus on the impact of lipid-lowering drugs on circulating PCSK9 concentration and its clinical implications in order to optimal consideration for the current strategies with regard to cholesterol control.
authors.affiliation: Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China.
authors.forename: Yuan-Lin
authors.initials: YL
authors.lastname: Guo
authors.affiliation: Department of Pathology, Beijing Hospital, Beijing 100730, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China. Electronic address: lijianjun938@yahoo.com.
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Li
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000097:blood; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000494:pharmacology*; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors* / Q000097:blood*; D012307:Risk Factors; D012697:Serine Endopeptidases / Q000097:blood*
chemical_list: D015415:Biomarkers; D000960:Hypolipidemic Agents; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases
keywords: Lipid profile; Lipid-lowering drug; Proprotein convertase subtilisin/kexin type 9; Review